74 related articles for article (PubMed ID: 14518336)
1. [The CD95/CD95L system as target for modulation of allogeneic immune responses].
Schwinzer R; Dulat H; Kyas U; Wonigeit K
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):655-8. PubMed ID: 14518336
[TBL] [Abstract][Full Text] [Related]
2. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.
Li-Weber M; Laur O; Dern K; Krammer PH
Eur J Immunol; 2000 Feb; 30(2):661-70. PubMed ID: 10671224
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells.
Dulat HJ; von Grumbkow C; Baars W; Schröder N; Wonigeit K; Schwinzer R
Eur J Immunol; 2001 Jul; 31(7):2217-26. PubMed ID: 11449376
[TBL] [Abstract][Full Text] [Related]
4. Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells.
Schütz C; Hoves S; Halbritter D; Zhang HG; Mountz JD; Fleck M
Immunology; 2011 May; 133(1):115-22. PubMed ID: 21342185
[TBL] [Abstract][Full Text] [Related]
5. Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity.
Strauss G; Osen W; Knape I; Jacobsen EM; Müller SM; Debatin KM
Cell Death Differ; 2007 Mar; 14(3):480-8. PubMed ID: 16902496
[TBL] [Abstract][Full Text] [Related]
6. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of activation-induced cell death in individual human T cell clones.
Janssen O; Stocker A; Sanzenbacher R; Oberg HH; Siddiqi MA; Kabelitz D
Int Arch Allergy Immunol; 2000 Mar; 121(3):183-93. PubMed ID: 10729776
[TBL] [Abstract][Full Text] [Related]
8. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly.
Holmström TH; Schmitz I; Söderström TS; Poukkula M; Johnson VL; Chow SC; Krammer PH; Eriksson JE
EMBO J; 2000 Oct; 19(20):5418-28. PubMed ID: 11032809
[TBL] [Abstract][Full Text] [Related]
9. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.
Strand S; Galle PR
Mol Med Today; 1998 Feb; 4(2):63-8. PubMed ID: 9547792
[TBL] [Abstract][Full Text] [Related]
10. Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death.
Stohl W; Xu D; Starling GC; Casali P; Kiener PA
Cell Immunol; 2000 Jul; 203(1):1-11. PubMed ID: 10915556
[TBL] [Abstract][Full Text] [Related]
11. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections.
Kusuhara M; Matsue H
Exp Dermatol; 2005 Apr; 14(4):273-80. PubMed ID: 15810885
[TBL] [Abstract][Full Text] [Related]
12. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparison of human xenogeneic and allogeneic proliferative cellular immune responses using serum-free media.
Saetre AM; Lillevang ST; Kemp E; Kristensen T
Transplant Proc; 1996 Apr; 28(2):656-7. PubMed ID: 8623329
[No Abstract] [Full Text] [Related]
14. A noncomitogenic CD2R monoclonal antibody induces apoptosis of activated T cells by a CD95/CD95-L-dependent pathway.
Fournel S; Robinet E; Bonnefoy-Bérard N; Assossou O; Flacher M; Waldmann H; Bismuth G; Revillard JP
J Immunol; 1998 May; 160(9):4313-21. PubMed ID: 9574534
[TBL] [Abstract][Full Text] [Related]
15. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand.
Müller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH
Eur J Immunol; 1995 Oct; 25(10):2996-9. PubMed ID: 7589104
[TBL] [Abstract][Full Text] [Related]
16. Alloantigen-induced human lymphocytes rendered nonresponsive by a combination of anti-CD80 monoclonal antibodies and cyclosporin-A suppress mixed lymphocyte reaction in vitro.
Comoli P; Montagna D; Moretta A; Zecca M; Locatelli F; Maccario R
J Immunol; 1995 Dec; 155(12):5506-11. PubMed ID: 7499831
[TBL] [Abstract][Full Text] [Related]
17. CD95 mediated T cell apoptosis and its relevance to immune deviation.
Varadhachary AS; Salgame P
Oncogene; 1998 Dec; 17(25):3271-6. PubMed ID: 9916989
[TBL] [Abstract][Full Text] [Related]
18. Stromal derived factor-1 alpha (SDF-1 alpha) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway.
Colamussi ML; Secchiero P; Gonelli A; Marchisio M; Zauli G; Capitani S
J Leukoc Biol; 2001 Feb; 69(2):263-70. PubMed ID: 11272277
[TBL] [Abstract][Full Text] [Related]
19. Relationship between proliferation and susceptibility to CD95- and CD2-mediated apoptosis in stimulated primary T lymphocytes: T cells manifesting proliferative unresponsiveness are preferentially susceptible to CD95-mediated apoptosis.
Mollereau B; Blanchard D; Déas O; Dumont C; Métivier D; Bernard A; McGrew JT; Charpentier B; Vazquez A; Senik A
J Immunol; 1997 Sep; 159(6):2668-77. PubMed ID: 9300686
[TBL] [Abstract][Full Text] [Related]
20. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells.
Zhang HG; Su X; Liu D; Liu W; Yang P; Wang Z; Edwards CK; Bluethmann H; Mountz JD; Zhou T
J Immunol; 1999 Feb; 162(3):1423-30. PubMed ID: 9973398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
